Inovio Pharma (INO) Reports Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall St futures pause after two-day rally as investors await data, earnings
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- U.S. headline producer inflation posts first one-month decrease since August 2025
- Oil eases as traders weigh US-Iran conflict risks
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
UPDATE: H.C. Wainwright Downgrades Inovio Pharmaceuticals (INO) to Neutral; 'Open Questions Remain'
June 29, 2020 6:19 AM EDT(Updated - June 29, 2020 6:37 AM EDT)
(updated to add analyst comments)
H.C. Wainwright analyst Raghuram Selvaraju downgraded Inovio Pharmaceuticals (NASDAQ: INO) from Buy to Neutral.
The analyst commented, "Last Friday, Inovio Pharmaceuticals shares ended trading at a market value of $4.7B. We note that the stock has had a satisfying run-up since Inovios initial receipt of funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of a DNA vaccine against COVID-19 on January 23, 2020, when the stock was trading at a market value of... More
Popular stocks with increasing volume: NKE GPS INO PCG
June 29, 2020 4:30 AM EDTPopular stocks with increasing volume: NKE GPS INO PCG
... MoreUPDATE: Inovio Pharmaceuticals (INO) PT Raised to $45 at Cantor Fitzgerald
June 26, 2020 6:44 AM EDT(Updated - June 26, 2020 9:01 AM EDT)
(updated to add analyst comments)
Cantor Fitzgerald analyst Charles Duncan raised its price target on Inovio Pharmaceuticals (NASDAQ: INO) to $45.00 (from $17.00) while maintaining an Overweight rating.
The analyst commented, ". We reiterate our Overweight rating and are raising... More
UPDATE: Stifel Downgrades Inovio Pharmaceuticals (INO) to Hold
June 26, 2020 4:16 AM EDT(Updated - June 26, 2020 5:19 AM EDT)
(updating comment)
Stifel analyst Stephen Willey downgraded Inovio Pharmaceuticals (NASDAQ: INO) from Buy to Hold with a price target of $24.00 (from $19.00).
The analyst comments "While acknowledging peer COVID-19 vaccine company valuations would suggest were potentially leaving... More
